Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases

Acta Pharmacologica Sinica

Volumn 23, Issue 12, 2002, Pages 1093-1101

  Lai, Jenn Haung ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Alkaloids; Autoimmune diseases; T lymphocytes; Tetrandrine

Indexed keywords

ANTIMALARIAL AGENT; ANTIOXIDANT; ANTIRHEUMATIC AGENT; ASCORBIC ACID; AZATHIOPRINE; BERBAMINE; BISBENZYLISOQUINOLINE ALKALOID; CHINESE DRUG; CORTICOSTEROID; CYCLOSPORIN; DAURICINE; FANGQUINOLINE; GLUCOCORTICOID; GLUTATHIONE; GOLD SALT; HERBACEOUS AGENT; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; ISOTETRANDRINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE C; SALAZOSULFAPYRIDINE; TACROLIMUS; TETRANDRINE; UNINDEXED DRUG;

ABDOMINAL DISTENSION; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; CELL DEATH; CHINESE MEDICINE; CLINICAL TRIAL; CONFERENCE PAPER; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DIARRHEA; DNA DAMAGE; DRUG EFFECT; DRY EYE; EFFECTOR CELL; ENDOTHELIUM CELL; HEART INFARCTION; HEART INFARCTION SIZE; HEART VENTRICLE ARRHYTHMIA; HERBAL MEDICINE; HUMAN; HUMAN CELL; HYPERPIGMENTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; NONHUMAN; PRURITUS; RAT; RHEUMATOID ARTHRITIS; SIDE EFFECT; SILICOSIS; T LYMPHOCYTE ACTIVATION;

ALKALOIDS; ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BENZYLISOQUINOLINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0036901923     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (83)

1. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications [see comments]. N Engl J Med 1996; 334: 1287-91.
2. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
3. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-56.
4. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: New perspectives. Arthritis Rheum 1997; 40: 598-609.
5. Weyand CM. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology 2000; 39: 3-8.
6. VanderBorght A, Geusens P, Raus J, Stinissen P. The autoimmune pathogenesis of rheumatoid arthritis: Role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 2001; 31: 160-75.
7. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27: 317-34.
8. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
9. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
10. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178: 1753-63.
11. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-7.
12. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g [see comments]. Science 1992; 257: 789-92.
13. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801-6.
14. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection [see comments]. Proc Natl Acad Sci USA 1996; 93: 12439-44.
15. Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309-18.
16. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 1996; 157: 4258-67.
17. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996; 272: 1939-43.
18. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-94.
19. Bai XF, Bender J, Liu J, Zhang H, Wang Y, Li O, et al. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 2001; 167: 3936-43.
20. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997; 94: 8099-103.
21. Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 1999; 163: 6912-23.
22. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997; 99: 439-46.
23. Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. J Immunol 1998; 161: 1018-25.
24. Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T. Apoptosis in rheumatoid arthritis: A novel pathway in the regulation of synovial tissue. Arthritis Rheum 1998; 41: 1-9.
25. Eguchi K. Apoptosis in autoimmune diseases. Internal Med 2001; 40: 275-84.
26. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
27. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54.
28. Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997; 185: 843-54.
29. Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: Implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
30. Levine JS, Koh JS, Pender MP. The role of apoptosis in autoimmunity: Immunogen, antigen, and accelerant: Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Semin Nephrol 1999; 19: 34-47.
31. Rovere P, Sabbadini MG, Fazzini F, Bondanza A, Zimmermann VS, Rugarli C, et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000; 43: 1663-72.
32. Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. J Immunol 1998; 161: 1018-25.
33. Nakajima H, Golstein P, Henkart PA. The target cell nucleus is not required for cell-mediated granzyme- or Fas-based cytotoxicity. J Exp Med 1995; 181: 1905-9.
34. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415-20.
35. Vaishnaw AK, McNally JD, Elkon KB. Apoptosis in the rheumatic diseases. Arthritis Rheum 1997; 40: 1917-27.
36. Pender MP. Genetically determined failure of activationinduced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998; 351: 978-81.
37. Hunig T, Schimpl A. Systemic autoimmune disease as a consequence of defective lymphocyte death. Curr Opin Immunol 1997; 9: 826-30.
38. Ohsako S, Elkon KB. Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis. Cell Death Differ 1999; 6: 13-21.
39. Hetts SW. To die or not to die: An overview of apoptosis and its role in disease. JAMA 1998; 279: 300-7.
40. Yocum DE. T cells: Pathogenic cells and therapeutic targets in rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 27-35.
41. Feng YX, Chen H. Pharmacognostic and chemical identification of Fang Ji (Stephania tetrandra). Chin J Pharm Anal 1985; 5: 28-31.
42. Li QL, Xu YH, Zhon ZH, Chen XW, Huang XG, Chen SL, et al. The therapeutic effect of tetrandrine on silicosis. Chin J Tuberc Res Dis 1981; 4: 321-8.
43. Li SY, Teh BS, Seow WK, Ling LH, Thong YH. Effect of tetrandrine on immunological responses and cardiac transplant rejection in mice. Int Arch Allergy Appl Immunol 1989; 90: 169-73.
44. Kondo Y, Imai Y, Hojo H, Hashimoto Y, Nozoe S. Selective inhibition of T-cell-dependent immune responses by bisbenzylisoquinoline alkaloids in vivo. Int J Immunopharmacol 1992; 14: 1181-6.
45. Whitehouse MW, Fairlie DP, Thong YH. Anti-inflammatory activity of the isoquinoline alkaloid, tetrandrine, against established adjuvant arthritis in rats. Agents Actions 1994; 42: 123-7.
46. Lai JH, Ho LJ, Kwan CY, Chang DM, Lee TC. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: Potential immunosuppressants in transplantation immunology. Transplantation 1999; 68: 1383-92.
47. Ho LJ, Chang DM, Lee TC, Chang ML, Lai JH. Plant alkaloid tetrandrine downregulates protein kinase C-dependent signaling pathway in T cells. Eur J Pharmacol 1999; 367: 389-98.
48. Newton AC. Protein kinase C: Structure, function, and regulation. J Biol Chem 1995; 270: 28495-8.
49. Hofmann J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 1997; 11: 649-69.
50. Liu J, Farmer JD, Lane WS Jr, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
51. Lieberman I, Heil BV, Seow WK, Thong YH. Synergy between tetrandrine and FK506 in prevention of diabetes in BB rats. Life Sci 1993; 53: PLA53-8.
52. Ferrante A, Seow WK, Rowan-Kelly B, Thong YH. Tetrandrine, a plant alkaloid, inhibits the production of tumour necrosis factor-alpha (cachectin) hy human monocytes. Clin Exp Immunol 1990; 80: 232-5.
53. Onai N, Tsunokawa Y, Suda M, Watanabe N, Nakamura K, Sugimoto Y, et al. Inhibitory effects of bisbenzylisoquinoline alkaloids on induction of proinflammatory cytokines, interleukin-1 and tumor necrosis factor-alpha. Planta Med 1995; 61: 497-501.
54. Chang DM, Chang WY, Kuo SY, Chang ML. The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 1997; 24: 436-41.
55. Xiao JG, Chiou GC. Tetrandrine inhibits breakdown of bloodaqueous barrier induced by endotoxin and interleukin-1 alpha in rats. J Ocular Pharmacol Ther 1996; 12: 323-9.
56. Kondo Y, Takano F, Hojo H. Inhibitory effect of bisbenzylisoquinoline alkaloids on nitric oxide production in activated macrophages. Biochem Pharmacol 1993; 46: 1887-92.
57. Zhou X. Tetrandrine on monocyte migration induced by endothelial cell-derived chemotactic factor. Chin Med J 1992; 72: 424-6.
58. Kobayashi S, Inaba K, Kimura I, Kimura M. Inhibitory effects of tetrandrine on angiogenesis in adjuvant-induced chronic inflammation and tube formation of vascular endothelial cells. Biol Pharm Bull 1998; 21: 346-9.
59. Seow WK, Li SY, Thong YH. Inhibitory effects of tetrandrine on human neutrophil and monocyte adherence. Immunol Lett 1986; 13: 83-8.
60. Shen YC, Chen CF, Sung YJ. Tetrandrine ameliorates ischaemia-reperfusion injury of rat myocardium through inhibition of neutrophil priming and activation. Br J Pharmacol 1999; 128: 1593-601.
61. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132: 38-42.
62. Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997; 40: 927-35.
63. Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995; 92: 7961-5.
64. Ho LJ, Chang DM, Chang ML, Kuo SY, Lai JH. Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J Rheumatol 1999; 26: 14-24.
65. Pang L, Hoult JR. Cytotoxicity to macrophages of tetrandrine, an antisilicosis alkaloid, accompanied by an overproduction of prostaglandins. Biochem Pharmacol 1997; 53: 773-82.
66. Lai YL, Chen YJ, Wu TY, Wang SY, Chang KH, Chung CH, et al. Induction of apoptosis in human leukemic U937 cells by tetrandrine. Anti-Cancer Drugs 1998; 9: 77-81.
67. Dong Y, Yang MM, Kwan CY. In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Life Sci 1997; 60: PL135-40.
68. Teh BS, Chen P, Lavin MF, Seow WK, Thong YH. Demonstration of the induction of apoptosis (programmed cell death) by tetrandrine, a novel anti-inflammatory agent. Int J Immunopharmacol 1991; 13: 1117-26.
69. Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, Han SH. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001; 166: 6914-24.
70. Cao ZF. Scavenging effect of tetrandrine of active oxygen radicals. Planta Med 1996; 62: 413-4.
71. Shi X, Mao Y, Saffiotti U, Wang L, Rojanasakul Y, Leonard SS, et al. Antioxidant activity of tetrandrine and its inhibition of quartz-induced lipid peroxidation. J Toxicol Environ Health 1995; 46: 233-48.
72. Matsuno T, Orita K, Edashige K, Kobuchi H, Sato EF, Inouye B, et al. Inhibition of active oxygen generation in guinea-pig neutrophils by biscoclaurine alkaloids. Biochem Pharmacol 1990; 39: 1255-9.
73. Seow WK, Ferrante A, Li SY, Thong YH. Antiphagocytic and antioxidant properties of plant alkaloid tetrandrine. Int Arch Allergy Appl Immunol 1988; 85: 404-9.
74. Ye J, Ding M, Zhang X, Rojanasakul Y, Shi X. On the role of hydroxyl radical and the effect of tetrandrine on nuclear factor-kappaB activation by phorbol 12-myristate 13-acetate. Ann Clin Lab Sci 2000; 30: 65-71.
75. Chen YJ, Tu ML, Kuo HC, Chang KH, Lai YL, Chung CH, et al. Protective effect of tetrandrine on normal human mononuclear cells against ionizing irradiation. Biol Pharm Bull 1997; 20: 1160-4.
76. Shen YC, Chen CF, Wang SY, Sung YJ. Impediment to calcium influx and reactive oxygen production accounts for the inhibition of neutrophil Mac-1 Up-regulation and adhesion by tetrandrine. Mol Pharmacol 1999; 55: 186-93.
77. Shen YC, Chou CJ, Chiou WF, Chen CF. Anti-inflammatory effects of the partially purified extract of radix Stephaniae tetrandrae: comparative studies of its active principles tetrandrine and fangchinoline on human polymorphonuclear leukocyte functions. Mol Pharmacol 2001; 60: 1083-90.
78. Wong CW, Seow WK, Thong YH. Comparative effects of tetrandrine and berbamine on acute and relapsing experimental allergic encephalitis in Lewis rats. Int Arch Allergy Immunol 1992; 97: 31-6.
79. Seow WK, Ferrante A, Summors A, Thong YH. Comparative effects of tetrandrine and berbamine on production of the inflammatory cytokines interleukin-1 and tumor necrosis factor. Life Sci 1992; 50: PL53-8.
80. Wong CW, Seow WK, O'Callaghan JW, Thong YH. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. Agents Actions 1992; 36: 112-8.
81. Li SY, Ling LH, Teh BS, Seow WK, Thong YH. Anti-inflammatory and immunosuppressive properties of the bisbenzylisoquinolines: In vitro comparisons of tetrandrine and berbamine. Int J Immunopharmacol 1989; 11: 395-401.
82. Teh BS, Seow WK, Li SY, Thong YH. Inhibition of prostaglandin and leukotriene generation by the plant alkaloids tetrandrine and berbamine. Int J Immunopharmacol 1990; 12: 321-6.
83. Wong CW, Seow WK, Zeng TS, Halliday WJ, Thong YH. Comparative immunopharmacology and toxicology of the bisbenzylisoquinoline alkaloids tetrandrine and berbamine. Int J Immunopharmacol 1991; 13: 579-85.